期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/ijms22020532
关键词
SARS-CoV-2; COVID-19; affinity-purification mass spectrometry; proximity-dependent biotin labeling (BioID); protein-protein interaction; proteomics; drug repurposing; virus; antiviral; emerging
资金
- Department of Experimental and Clinical Medicine
- fellowship of the Ph.D. Program in Life Sciences
Protein-protein interactions play crucial roles in viral lifecycle regulation, and high-throughput mass spectrometry techniques offer efficient tools to identify drug targets. Mapping and validating key targets through PPIs and multi-omics experiments provide promising opportunities for antiviral drug discovery, especially through drug repurposing, which may be a cost-effective and time-saving approach in the fight against COVID-19.
Protein-protein interactions (PPIs) are the vital engine of cellular machinery. After virus entry in host cells the global organization of the viral life cycle is strongly regulated by the formation of virus-host protein interactions. With the advent of high-throughput -omics platforms, the mirage to obtain a high resolution view of virus-host interactions has come true. In fact, the rapidly expanding approaches of mass spectrometry (MS)-based proteomics in the study of PPIs provide efficient tools to identify a significant number of potential drug targets. Generation of PPIs maps by affinity purification-MS and by the more recent proximity labeling-MS may help to uncover cellular processes hijacked and/or altered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), providing promising therapeutic targets. The possibility to further validate putative key targets from high-confidence interactions between viral bait and host protein through follow-up MS-based multi-omics experiments offers an unprecedented opportunity in the drug discovery pipeline. In particular, drug repurposing, making use of already existing approved drugs directly targeting these identified and validated host interactors, might shorten the time and reduce the costs in comparison to the traditional drug discovery process. This route might be promising for finding effective antiviral therapeutic options providing a turning point in the fight against the coronavirus disease-2019 (COVID-19) outbreak.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据